Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Fast Is The Graft Versus Host Disease (GVHD) Treatment Market Expected to Grow Between 2025 And 2029?
The market size for the treatment of graft versus host disease (GVHD) has been on a significant upsurge in the recent past. It’s projected to escalate from a worth of $2.85 billion in 2024, to approximately $3.06 billion in 2025, with a compound annual growth rate (CAGR) of 7.4%. Factors contributing to the substantial growth experienced in the historic period include an upsurge in the quantity of allogeneic transplantations, a growing occurrence of acute GVHD, an escalated rate of hematopoietic stem cell treatments, an increased demand for bone marrow transplants, a burgeoning prevalence of GVHD globally, a rise in chronic GVHD incidences, technological advancements and a growing patient count.
Projections are indicating a substantial expansion in the market for graft versus host disease (gvhd) treatment over the next several years, with an estimation that it will reach$4 billion by 2029″ growing at a CAGR of 6.9%. Several factors can be credited for this anticipated growth, including an upsurge in allogeneic transplantations, heightened occurrence of acute GVHD, accelerated hematopoietic stem cell treatment rates, growing demand for bone marrow transplants, increased global prevalence of GVHD, a rise in chronic GVHD instances, technological advancements, as well as a growing patient demographic. Notable trends expected during this forecast period comprise of partnerships, investments, and product approvals, alongside customizations.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15579&type=smp
What are the Fundamental Drivers and Innovations Shaping the Graft Versus Host Disease (GVHD) Treatment Market?
The increase in hematological disorders is anticipated to boost the expansion of the graft versus host disease (GVHD) treatment market. These blood disorders are an expansive category of conditions involving blood and its components such as red and white blood cells, platelets and plasma. A variety of factors like unhealthy lifestyle habits, genetic factors, and exposure to environmental toxins like radiation, chemicals, and pollutants are expanding the scope of hematological disorders. The methods developed for GVHD treatment can have substantial impacts on patients suffering from hematological disorders, paving the way for immune modulation and improved disease control. For example, the Leukemia & Lymphoma Society, based in the US, projected that Leukemia, lymphoma, and myeloma would be responsible for an estimated 57,380 deaths in the US in 2023. This translates to approximately 157 daily deaths or over six people dying every hour from blood cancer in the US. Thus, the surge in hematological disorders fuels the graft versus host disease (GVHD) treatment market growth.
How Is the Graft Versus Host Disease (GVHD) Treatment Market Segmented?
The graft versus host disease (gvhd) treatmentmarket covered in this report is segmented –
1) By Product Type: Corticosteroids; Monoclonal Antibodies; Immunosuppressants; Others
2) By Disease Type: Acute GvHD; Prophylaxis GvHD; Chronic GvHD
3) By End User: Hospitals Pharmacies; Retail Pharmacies; Online Pharmacies
Subsegments:
1) By Corticosteroids: Prednisolone; Methylprednisolone; Dexamethasone; Hydrocortisone; Betamethasone; Budesonide
2) By Monoclonal Antibodies: Anti-Inf Monoclonal Antibodies ( Infliximab, Adalimumab); Anti-il-2rα Monoclonal Antibodies ( Basiliximab); Anti-cd52 Monoclonal Antibodies (Alemtuzumab); Anti-il-6 Monoclonal Antibodies (Tocilizumab); Anti-Cd20 Monoclonal Antibodies (Rituximab)
3) By Immunosuppressants: Calcineurin Inhibitors (Cyclosporine, Tacrolimus); Methotrexate; Mycophenolate Mofetil; Azathioprine; Sirolimus (Rapamycin); Cyclophosphamide
4) By Others: Mesenchymal Stem Cells (Mscs); Jak Inhibitors ( Ruxolitinib); Extracorporeal Photopheresis (Ecp); Thalidomide; Antithymocyte Globulin (Atg); Colony-Stimulating Factors (Filgrastim)
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=15579&type=smp
Which Regions Are Driving the Next Phase of the Graft Versus Host Disease (GVHD) Treatment Market Growth?
North America was the largest region in the graft versus host disease (GVHD) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the graft versus host disease (GVHD) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Key Trends Are Shaping the Future of the Graft Versus Host Disease (GVHD) Treatment Market?
Leading businesses in the graft versus host disease (GVHD) treatment sector are focusing on advancing their drugs and gaining approval to propel their market standing. Obtaining approval is essential to ensure that medical products adhere to the required safety, effectiveness, and quality standards before they are provided to patients. For example, Incyte corporation, a healthcare firm based in the US, was able to get approval for their ruxolitinib extended-release (XR) tablets, a JAK1/JAK2 inhibitor, from the Food and Drug Administration in March 2023. The tablets are prescribed for once-daily use to treat specific categories of myelofibrosis, polycythemia vera, and graft-versus-host disease (GVHD).
View the full report here:
How Is the Graft Versus Host Disease (GVHD) Treatment Market Defined and What Are Its Core Parameters?
Graft versus host disease (GVHD) treatment involves various medical interventions aimed at managing or alleviating the complications arising from GVHD, a condition where transplanted donor cells attack the recipient’s tissues. It is used to control the consequences that arise from GVHD, a disease in which the tissues of the recipient are attacked by transplanted donor cells.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15579
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model